

April 15, 2025

Direct Healthcare Professional Communication

Dompy (domperidone) is not indicated in pediatric patients under 12 years of age or weighing less than 35 kg

Dear Healthcare professional,

Jamjoom Pharmaceutical Factory Company, in agreement with Saudi Drug and Food Authority (SFDA), would like to remind you about the approved indications of Dompy (domperidone).

Summary:

- The only registered indication for Dompy (domperidone) is the relief of symptoms of nausea and vomiting in adults and adolescents 12 years of age and older and weighing 35 kg or more.
- The indication in younger children has been previously deleted.
- Domperidone should be used at the lowest effective dose for the shortest duration necessary to control nausea and vomiting. The maximum treatment duration should not usually exceed 1 week.
- For adults and adolescents (over 12 years and weighing 35 kg or more), the recommended dose is 10mg up to three times daily with a maximum oral daily dose of 30 mg.
- Reminder of contraindications:

Dompy (Domperidone) is contraindicated in the following situations:

- Known hypersensitivity to domperidone or any of the excipients
- Prolactin-releasing pituitary tumour (prolactinoma).
- when stimulation of the gastric motility could be harmful e.g. in patients with gastro-intestinal haemorrhage, mechanical obstruction or perforation.
- in patients with moderate or severe hepatic impairment.
- in patients who have known existing prolongation of cardiac conduction intervals, particularly QTc, patients with significant electrolyte disturbances or underlying cardiac diseases such as congestive heart failure.
- co-administration with QT-prolonging drugs.
- co-administration with potent CYP3A4 inhibitors (regardless of their QT prolonging effects).



Page 1 of 2

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.



شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ٤٠٣٠١٥٤٩٦

عنوان المصنع : رقم القطعة م : ٣ : ١ المنطقة الصناعية، المرحلة الخامسة، جدة ، ت : ٩٦٦ ١٢ ٦٠٨ ١١١١ ، ف : ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي : ٦٢٦٧ ، جدة - ٢١٤٤٢ ، المملكة العربية السعودية، الإدارة : ت : ٩٦٦ ١٢ ٦١٤ ٠٠٩٩ ، ف : ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222
Postal Address P.O.Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088
E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

Background:

This communication is sent to remind healthcare providers that the only registered indication for Dompy (domperidone) is the relief of symptoms of nausea and vomiting in adults and adolescents 12 years of age and older and weighing 35 kg or more.

In 2020, the indication for its use in children younger than 12 years or those weighing less than 35 kg was removed following the results from a randomized-controlled study showing that the use of domperidone in children below 12 years of age with acute gastroenteritis (in combination with oral rehydration therapy) had no difference in efficacy when compared to placebo.¹

Advice for Healthcare Providers:

Healthcare providers should adhere to the locally approved indications and posology.

- Domperidone should not be used in infants and children less than 12 years of age who weigh less than 35 kg due to lack of efficacy in this population.
- Be aware of the contraindications associated with the use of Domperidone.
- Prescribe domperidone at the lowest effective dose and for the shortest duration possible.
- For adults and adolescents (over 12 years and weighing 35 kg or more), the recommended dose is 10 mg up to three times daily with a maximum oral daily dose of 30 mg.
- Use for the shortest possible duration which should not usually exceed 1 week

Call for reporting:

We encourage healthcare providers to report any side effect(s) to:

Jamjoom Pharmaceutical Factory Company

Jamjoom Pharma Pharmacovigilance Department

Corporate Office: Tel: +966 126140099 Ext #3259/ #3055

P.O. Box: 6267 Jeddah 21442, Saudi Arabia

E-mail: Pharmacovigilance@jamjoompharma.com

Website: www.jamjoompharma.com

Saudi Food and Drug Authority

National Pharmacovigilance Center

Email: npc.drug@sfd.a.gov.sa

Call Center: 19999

Website: <https://ade.sfd.a.gov.sa/>



References:

1. Leitz, G., Hu, P., Appiani, C., Li, Q., Mitha, E., Garcés-Sánchez, M., & Gupta, R. (2019). Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children. *Journal of pediatric gastroenterology and nutrition*, 69(4), 425–430. <https://doi.org/10.1097/MPG.0000000000002409>

Yours sincerely,

Lujain Altayeb

QPPV (Qualified Person for Pharmacovigilance)

Page 2 of 2

شركة مساهمة - رأس المال ٧٠٠ مليون ريال، س.ت. ١٥٤٥٩٦-٤٠٣٠

عنوان المصنع : رقم القطعة م . ي ١ : ٣، المنطقة الصناعية، المرحلة الخامسة، جدة، ت: ٩٦٦ ١٢ ٦٠٨ ١١١١، ف: ٩٦٦ ١٢ ٦٠٨ ١٢٢٢
العنوان البريدي: ٦٢٦٧، جدة - ٢١٤٤٢، المملكة العربية السعودية، الإدارة: ت: ٩٦٦ ١٢ ٦١٤ ٠٠٩٩، ف: ٩٦٦ ١٢ ٦١٤ ٠٠٨٨

Joint Stock Company - Capital SR. 700 Million, C.R. 4030154596

Factory Address: Plot No. ME1 : 3, Phase V, Industrial City, Jeddah, Tel.: + 966 12 608 1111, Fax: + 966 12 608 1222

Postal Address P.O. Box 6267, Jeddah 21442 Saudi Arabia, Administration: Tel.: + 966 12 614 0099, Fax: + 966 12 614 0088

E-mail: jpharma@jamjoompharma.com - Website: www.jamjoompharma.com

شركة مصنع جمجوم للأدوية
Jamjoom Pharmaceuticals Factory Co.

